Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 20

1.

Muir-Torre syndrome.

Ponti G, Ponz de Leon M.

Lancet Oncol. 2005 Dec;6(12):980-7. Review.

PMID:
16321766
2.

Muir-Torre syndrome.

Lachiewicz AM, Wilkinson TM, Groben P, Ollila DW, Thomas NE.

Am J Clin Dermatol. 2007;8(5):315-9.

PMID:
17902735
3.

The Muir-Torre syndrome: a 25-year retrospect.

Schwartz RA, Torre DP.

J Am Acad Dermatol. 1995 Jul;33(1):90-104. Review.

PMID:
7601953
4.

Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a diagnostic algorithm.

Abbas O, Mahalingam M.

J Cutan Pathol. 2009 Jun;36(6):613-9. doi: 10.1111/j.1600-0560.2009.01248.x. Review.

PMID:
19515040
5.

Screening for Muir-Torre syndrome using mismatch repair protein immunohistochemistry of sebaceous neoplasms.

Roberts ME, Riegert-Johnson DL, Thomas BC, Thomas CS, Heckman MG, Krishna M, DiCaudo DJ, Bridges AG, Hunt KS, Rumilla KM, Cappel MA.

J Genet Couns. 2013 Jun;22(3):393-405. doi: 10.1007/s10897-012-9552-4. Epub 2012 Dec 6.

PMID:
23212176
6.

Sebaceous neoplasia and the Muir-Torre syndrome: important connections with clinical implications.

Shalin SC, Lyle S, Calonje E, Lazar AJ.

Histopathology. 2010 Jan;56(1):133-47. doi: 10.1111/j.1365-2559.2009.03454.x. Review.

7.

Muir-Torre syndrome: case report and review of the literature.

Ang JM, Alai NN, Ritter KR, Machtinger LA.

Cutis. 2011 Mar;87(3):125-8.

PMID:
21488569
8.

Muir-Torre syndrome: a case report and review of the literature.

Okan G, Vural P, Ince Ü, Yazar A, Uras C, Saruç M.

Turk J Gastroenterol. 2012 Aug;23(4):394-8. Review.

9.
10.

MSH-2 and MLH-1 protein expression in Muir Torre syndrome-related and sporadic sebaceous neoplasms.

Morales-Burgos A, Sánchez JL, Figueroa LD, De Jesús-Monge WE, Cruz-Correa MR, González-Keelan C, Nazario CM.

P R Health Sci J. 2008 Dec;27(4):322-7.

11.

MSH6 mutation in a family affected by Muir-Torre syndrome.

Kacerovska D, Cerna K, Martinek P, Grossmann P, Michal M, Ricar J, Kazakov DV.

Am J Dermatopathol. 2012 Aug;34(6):648-52. doi: 10.1097/DAD.0b013e3182446fe2.

PMID:
22814321
12.

Microsatellite instability and immunostaining for MSH-2 and MLH-1 in cutaneous and internal tumors from patients with the Muir-Torre syndrome.

Machin P, Catasus L, Pons C, Muñoz J, Conde-Zurita JM, Balmaña J, Barnadas M, Martí RM, Prat J, Matias-Guiu X.

J Cutan Pathol. 2002 Aug;29(7):415-20.

PMID:
12139636
13.

Germline mutation in MSH6 associated with multiple malignant neoplasms in a patient With Muir-Torre syndrome.

Tavakkol Z, Keller JJ, Furmanczyk PS, Bennett RL, Chien AJ.

J Clin Oncol. 2012 Aug 1;30(22):e195-8. doi: 10.1200/JCO.2011.41.5562. Epub 2012 Jun 25. No abstract available.

PMID:
22734033
14.

Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas.

Ponti G, Losi L, Pedroni M, Lucci-Cordisco E, Di Gregorio C, Pellacani G, Seidenari S.

J Invest Dermatol. 2006 Oct;126(10):2302-7. Epub 2006 Jul 6.

15.
16.

Clinical, dermoscopic and reflectance confocal microscopy features of sebaceous neoplasms in Muir-Torre syndrome.

Moscarella E, Argenziano G, Longo C, Cota C, Ardigò M, Stigliano V, Mete LS, Donati P, Piana S, Silipo V, Catricalà C, Albertini G, Zalaudek I.

J Eur Acad Dermatol Venereol. 2013 Jun;27(6):699-705. doi: 10.1111/j.1468-3083.2012.04539.x. Epub 2012 Apr 4.

PMID:
22471909
17.

The frequency of Muir-Torre syndrome among Lynch syndrome families.

South CD, Hampel H, Comeras I, Westman JA, Frankel WL, de la Chapelle A.

J Natl Cancer Inst. 2008 Feb 20;100(4):277-81. doi: 10.1093/jnci/djm291. Epub 2008 Feb 12.

PMID:
18270343
18.
19.

Muir-Torre syndrome.

Mercader P.

Adv Exp Med Biol. 2010;685:186-95. Review.

PMID:
20687506
20.

[Muir-Torre syndrome--a phenotypic variant of Lynch syndrome].

Kacerovská D, Kazakov DV, Cerná K, Hadravský L, Michal M Jr, Dostál J, Skálová A Jr, Michal M.

Cesk Patol. 2010 Oct;46(4):86-94. Review. Czech.

PMID:
21313735

Supplemental Content

Support Center